Cargando…

The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor‐positive breast cancer: A single‐institute retrospective study

BACKGROUND: Higher body mass index (BMI) is associated with worse prognosis in pre‐ and postmenopausal patients with breast cancer (BC). However, there is insufficient evidence regarding the optimal adjuvant endocrine therapy for obese premenopausal women with hormone receptor (HR)‐positive BC. AIM:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozaki, Yukinori, Masuda, Jun, Kataoka, Akemi, Kogawa, Takahiro, Abe, Tomomi, Morizono, Hidetomo, Inagaki, Lina, Hara, Fumikata, Takano, Toshimi, Ueno, Takayuki, Ohno, Shinji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940008/ https://www.ncbi.nlm.nih.gov/pubmed/36806718 http://dx.doi.org/10.1002/cnr2.1695

Ejemplares similares

Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment Center
por: Ozaki, Yukinori, et al.
Publicado: (2021)

MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer
por: Inagaki, Lina, et al.
Publicado: (2021)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer
por: Fukada, Ippei, et al.
Publicado: (2022)

Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial
por: Funasaka, Chikako, et al.
Publicado: (2023)

Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report
por: Maeshima, Yurina, et al.
Publicado: (2021)

Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study
por: Ozaki, Yukinori, et al.
Publicado: (2018)

A Case of Recurrent Breast Cancer Identified by Pulmonary Tumor Thrombotic Microangiopathy
por: Abe, Tomomi, et al.
Publicado: (2017)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
por: Chin, Yoon Ming, et al.
Publicado: (2022)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
por: Inoue, Yuka, et al.
Publicado: (2022)

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
por: Ueno, Takayuki, et al.
Publicado: (2019)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin
por: Saeki, Sumito, et al.
Publicado: (2023)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010)

Usefulness of second-look ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities
por: Izumori, Ayumi, et al.
Publicado: (2019)

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1990)

Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan
por: Miyashita, Mika, et al.
Publicado: (2015)

Paracrine and endocrine functions of osteocytes
por: Michigami, Toshimi
Publicado: (2022)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Label‐free multiphoton excitation imaging as a promising diagnostic tool for breast cancer
por: Matsui, Takahiro, et al.
Publicado: (2022)

Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial
por: Takano, Toshimi, et al.
Publicado: (2021)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
por: Masuda, Takaaki, et al.
Publicado: (2020)

Measurement of endometrial thickness in premenopausal women in office gynecology
por: Tsuda, Hiroshi, et al.
Publicado: (2017)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
por: Xu, Lei, et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
por: Masuda, Norikazu, et al.
Publicado: (2018)

Premenopausal osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2013)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gveikbhcd94n27e3qd0re50r6i